A new formulation of AstraZeneca (NYSE: AZN)’s prescription proton pump inhibitor -NEXIUM® (esomeprazole magnesium) - has recently been approved by the USFDA.
The new NEXIUM® For Delayed-Release Oral Suspension is now approved for the treatment of GERD, including symptomatic gastroesophageal reflux disease (GERD), healing and maintenance of healing of erosive esophagitis (EE), and risk reduction of NSAID-associated gastric (stomach) ulcers.
The only difference is that, in this new formulation, the esomeprazole granules and inactive granules are mixed with water to form a suspension and are given by oral, nasogastric or gastric administration.
The new formulation: NEXIUM® For Delayed-Release Oral Suspension will be available in the first quarter of 2007. 
The same active ingredient used in NEXIUM® Delayed-Release Capsules, esomeprazole, is contained in either 20 mg or 40 mg dosage in every packet of NEXIUM® For Delayed-Release Oral Suspension.
Find more details from the press release.
Comment Preview